A pharmaceutical composition comprising a compound of formula and a pharmaceutically acceptable excipient, for use in a method of treating a disorder by modulating a glucocorticoid receptor, wherein the disorder is Cushing's syndrome, hypercortisolemia, hyperglycemia, diabetes, hypertension or cardiovascular disease, the compound having the formula: wherein R 1 is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from R 1a; each R 1a is independently selected from the group consisting of hydrogen, C 1-6 alkyl, halogen, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, -CN, N-oxide, C 3-8 cycloalkyl, and C 3-8 heterocycloalkyl; ring J is selected from the group consisting of a cycloalkyl ring, a heterocycloalkyl ring, an aryl ring and a heteroaryl ring, wherein the heterocycloalkyl and heteroaryl rings have from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S; each R 2 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, halogen, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkyl-C 1-6 alkoxy, -CN, -OH, -NR 2a R 2b, -C R 2a, -C OR 2a, -C NR 2a R 2b, -SR 2a, -S R 2a, -S 2 R 2a, C 3-8 cycloalkyl, and C 3-8 heterocycloalkyl, wherein the heterocycloalkyl groups are optionally substituted with 1-4 R 2c groups; alternatively, two R 2 groups linked to the same carbon are combined to form an oxo group (=O); alternatively, two R 2 groups are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 R 2d groups; R 2a and R 2b are each independently selected from the group consisting of hydrogen and C 1-6 alkyl; each R 2c is independently selected from the group consisting of hydrogen, halogen, hydroxy, C 1-6 alkoxy, C 1-6 haloalkoxy, -CN, and -NR 2a R 2b; each R 2d is independently selected from the group consisting of hydrogen and C 1-6 alkyl, or two R 2d groups attached to the same ring atom are combined to form (=O); R 3 is selected from the group consisting of phenyl and pyridyl, each optionally substituted with 1-4 R 3a groups; each R 3a is independently selected from the group consisting of hydrogen, halogen, and C 1-6 haloalkyl; subscript n is an integer from 0 to 3; or a salt thereof. R 1 is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from R 1a; each R 1a is independently selected from the group consisting of hydrogen, C 1-6 alkyl, halogen, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, -CN, N-oxide, C 3-8 cycloalkyl, and C 3-8 heterocycloalkyl; ring J is selected from the group consisting of a cycloalkyl ring, a heterocycloalkyl ring, an aryl ring and a heteroaryl ring, wherein the heterocycloalkyl and heteroaryl rings have from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S; each R 2 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, halogen, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkyl-C 1-6 alkoxy, -CN, -OH, -NR 2a R 2b, -C R 2a, -C OR 2a, -C NR 2a R 2b, -SR 2a, -S R 2a, -S 2 R 2a, C 3-8 cycloalkyl, and C 3-8 heterocycloalkyl, wherein the heterocycloalkyl groups are optionally substituted with 1-4 R 2c groups; alternatively, two R 2 groups linked to the same carbon are combined to form an oxo group (=O); alternatively, two R 2 groups are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 R 2d groups; R 2a and R 2b are each independently selected from the group consisting of hydrogen and C 1-6 alkyl; each R 2c is independently selected from the group consisting of hydrogen, halogen, hydroxy, C 1-6 alkoxy, C 1-6 haloalkoxy, -CN, and -NR 2a R 2b; each R 2d is independently selected from the group consisting of hydrogen and C 1-6 alkyl, or two R 2d groups attached to the same ring atom are combined to form (=O); R 3 is selected from the group consisting of phenyl and pyridyl, each optionally substituted with 1-4 R 3a groups; each R 3a is independently selected from the group consisting of hydrogen, halogen, and C 1-6 haloalkyl;